Assessment of the economic feasibility of gadoversetamida (OptiMARK) MRI with intravenous contrast

Autor:	A. S. Kolbin, I. A. Vilum
Jazyk:	ruština
Rok vydání:	2018
Předmět:	lcsh:Pharmacy and materia medica cost-minimizing analysis lcsh:Medical technology lcsh:R855-855.5 cost-effectiveness analysis contrast enhancement lcsh:RS1-441 budget impact analysis mri health economic evaluation
Zdroj:	Качественная клиническая практика, Vol 0, Iss 2, Pp 21-26 (2018)
ISSN:	2618-8473 2588-0519
Popis:	Gadolinium based contrast agents are widely used in MRI in a diagnostic of variety of pathologies. The quality of contrast enhancement depends on the total dose. The aim of the study is to conduct a health economic evaluation of gadoversetamide (OptiMARK, Malickrodt Pharmaceuticals) in contrast enhanced MRI. The cost-effectiveness analysis, costminimizing analysis and sensitivity analysis and budget impact analysis were used modeling contrast enhanced MRI. In results, we can say that OptiMARK is cost-effective comparing to gadopentetic acid and gadobutrol.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doajarticles::0d8a64fdf6ef46fa394f3dc499f7e16f https://www.clinvest.ru/jour/article/view/201 Zobrazit plný text záznamu